Heranova is actively recruiting U.S. clinical sites to participate in a flagship validation study for its lead product, HerResolve, a non-invasive, blood-based diagnostic assay for confirming the presence or absence of endometriosis in symptomatic women.
This is a prospective and retrospective observational study for women ages 18-49 years that intends to enroll hundreds of patients from multiple community and academic women’s health centers across the U.S. Site requirements and patient involvement are convenient and very minimal.
Contact Clinical Affairs today to learn more about participating: